AI will solve everything including longevity

AI will solve everything including longevity | >> But it's it's safe to say it will it will solve everything you can possibly think of. >> Yes. >> Uh longevity being, you know, certainly one of them.

Watch events: Life Biosciences ER-100 Phase 1 first readout (likely late 2026/early 2027)

>> But it's it's safe to say it will it will solve everything you can possibly think of. >> Yes. >> Uh longevity being, you know, certainly one of them.

Musk 'AI solves everything + longevity' — aspiration, no timeline.

Beneficiaries (14)

Adverse (7)

{
  "nia": false,
  "url": "https://www.youtube.com/watch?v=N5KCm_55xeQ",
  "mode": "PREDICTION",
  "role": "Guest-CEO",
  "context": "it will it will solve everything you can possibly think of. >> Yes.",
  "verbatim": ">> But it's it's safe to say it will it will solve everything you can possibly think of. >> Yes. >> Uh longevity being, you know, certainly one of them.",
  "conv_cues": "Yes (affirmative)",
  "direction": "HAPPEN",
  "timeframe": "future, unspecified",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "llm_pre_event",
      "label": "FDA mAbs-roadmap NAM (organoids/in-silico) replaces animal testing in major IND",
      "notes": "HIT - FDA mAbs-first roadmap explicitly cited; sets the regulatory precedent that AI/in-silico screening can be primary.",
      "source": "https://www.drugdiscoveryonline.com/doc/2025s-top-drug-discovery-highlights-and-how-to-stay-ahead-in-2026-0001",
      "status": "hit",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.85,
      "source_url": "https://www.drugdiscoveryonline.com/doc/2025s-top-drug-discovery-highlights-and-how-to-stay-ahead-in-2026-0001",
      "expected_date": "2026-04-30",
      "observed_date": "2026-04-30",
      "research_origin": "deep_research",
      "measurement_criterion": "FDA approves a New Approach Methodology (organoid, tissue-chip, or in-silico) as primary safety screen replacing animal testing in a monoclonal antibody IND"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q1 window check-in (25%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -6,
      "source_id": null,
      "expected_date": "2026-07-28",
      "observed_date": null
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q2 window check-in (50%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -5,
      "source_id": null,
      "expected_date": "2026-10-25",
      "observed_date": null
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q3 window check-in (75%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -4,
      "source_id": null,
      "expected_date": "2027-01-22",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "AI-discovered longevity candidate enters Phase I clinical trial",
      "source": "https://lifespan.io/news/an-ai-based-system-has-found-a-potential-longevity-drug/",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -3,
      "source_id": null,
      "confidence": 0.65,
      "source_url": "https://lifespan.io/news/an-ai-based-system-has-found-a-potential-longevity-drug/",
      "expected_date": "2027-01-30",
      "research_origin": "deep_research",
      "expected_date_range": {
        "to": "2027-09-30",
        "from": "2026-06-01"
      },
      "measurement_criterion": "An AI-discovered molecule targeting aging hallmarks (senolytics, partial reprogramming, mTOR, NAD+) reaches Phase I clinical trial with FDA IND filing publicly disclosed"
    },
    {
      "kind": "llm_pre_event",
      "label": "Isomorphic Labs / Insilico Medicine announces AI-designed clinical candidate",
      "source": "Isomorphic Labs press; Insilico Medicine investor calls",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -2,
      "source_id": null,
      "confidence": 0.7,
      "expected_date": "2027-03-17",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2027-12-31",
        "from": "2026-06-01"
      },
      "measurement_criterion": "Isomorphic Labs (Demis Hassabis), Insilico, or Recursion publicly announces a wholly AI-designed compound in human trials with reasoning model attribution"
    },
    {
      "kind": "llm_pre_event",
      "label": "AI lab claims demonstrable solution to a major scientific problem (publicly verified)",
      "source": "Nature, Science, peer-reviewed lab papers",
      "status": "pending",
      
... (truncated)